We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+12.78%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$208M
AUM Growth
+$29.3M
Cap. Flow
+$24.3M
Cap. Flow %
11.67%
Top 10 Hldgs %
53.69%
Holding
72
New
35
Increased
16
Reduced
9
Closed
7

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.44M
2
DERM
Dermira, Inc.
DERM
+$4.69M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$4.6M
4
IRIX icon
IRIDEX
IRIX
+$4.41M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$2.88M

Top Sells

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$9.36M
2
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$6.39M
3
CPXX
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
+$5.51M
4
SBBP
Strongbridge Biopharma plc.
SBBP
+$4.51M
5
IMMU
Immunomedics Inc
IMMU
+$4.43M

Sector Composition

Rank Sector Weight
1 Healthcare 73.3%
2 Technology 1.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOVA icon
1
Iovance Biotherapeutics
IOVA
$1.93B
$26.2M 12.58%
3,232,416
+732,416
+29% +$4.6M
VCYT icon
2
Veracyte
VCYT
$3.58B
$16M 7.71%
3,187,607
+450,965
+16% +$2.42M
IRIX icon
3
IRIDEX
IRIX
$14.4M
$15M 7.19%
1,011,871
+354,201
+54% +$4.41M
NDRM
4
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$10.3M 4.95%
634,000
-192,799
-23% -$3.25M
IMMU
5
DELISTED
Immunomedics Inc
IMMU
$9.74M 4.68%
4,200,000
-1,326,172
-24% -$4.43M
RRM
6
DELISTED
RR MEDIA LTD ORD SHS (ISR)
RRM
$8M 3.84%
611,818
+3,500
+0.6% +$45.8K
EVDY
7
DELISTED
Everyday Health, Inc.
EVDY
$7.45M 3.58%
945,000
+120,500
+15% +$772K
CASM
8
DELISTED
CAS Medical Systems, Inc.
CASM
$6.44M 3.1%
3,500,602
+821,849
+31% +$1.54M
FOLD
9
DELISTED
Amicus Therapeutics
FOLD
$6.34M 3.05%
1,161,545
-1,338,455
-54% -$9.36M
ASND icon
10
Ascendis Pharma A/S
ASND
$16B
$6.27M 3.01%
472,800
-150,831
-24% -$2.32M
IWM icon
11
PUT
iShares Russell 2000 ETF
IWM
$81.5B
$5.75M 2.76%
50,000
– –
PDSB icon
12
PDS Biotechnology
PDSB
$40M
$5.36M 2.57%
26,500
+7,245
+38% +$1.28M
BMRN icon
13
BioMarin Pharmaceuticals
BMRN
$11.6B
$4.98M 2.39%
+64,000
New +$5.44M
DERM
14
DELISTED
Dermira, Inc.
DERM
$4.97M 2.39%
+170,000
New +$4.69M
AKBA icon
15
Akebia Therapeutics
AKBA
$351M
$4.49M 2.16%
600,000
+213,692
+55% +$1.87M
NBRV
16
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$4.19M 2.01%
2,235
+55
+3% +$111K
OXFD
17
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$3.76M 1.8%
417,278
+109,234
+35% +$1.07M
CEMP
18
DELISTED
Cempra, Inc.
CEMP
$3.46M 1.66%
210,000
– –
INNL
19
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$3.13M 1.5%
568,137
+190,372
+50% +$1.56M
MDVN
20
DELISTED
MEDIVATION, INC.
MDVN
$3.02M 1.45%
+50,000
New +$2.84M
ACAD icon
21
Acadia Pharmaceuticals
ACAD
$4.39B
$2.79M 1.34%
+85,999
New +$2.88M
TSRO
22
DELISTED
TESARO, Inc.
TSRO
$2.52M 1.21%
+30,000
New +$1.34M
SRPT icon
23
Sarepta Therapeutics
SRPT
$1.68B
$2.48M 1.19%
+130,000
New +$2.41M
MRVL icon
24
Marvell Technology
MRVL
$174B
$2.28M 1.1%
+239,588
New +$2.4M
PODD icon
25
Insulet
PODD
$11.8B
$2.27M 1.09%
+75,000
New +$2.33M
1
2 3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2016 Portfolio in Review

As of Q2 2016, Acuta Capital Partners held 72 positions worth $208M, up 16% from $179M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Acuta Capital Partners deployed $24.3M of net new capital in Q2 2016, opening 35 new positions and adding to 16 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 64,000 shares worth $4.98M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 69% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Amicus Therapeutics, an estimated $9.36M trimmed.

  • Acuta Capital Partners's largest Q2 2016 buy was BioMarin Pharmaceuticals: 64,000 shares worth $4.98M.
  • Acuta Capital Partners added most to Iovance Biotherapeutics in Q2 2016, an estimated $4.6M increase.
  • Acuta Capital Partners's biggest Q2 2016 reduction was Amicus Therapeutics, cutting an estimated $9.36M.
  • Acuta Capital Partners fully exited CELATOR PHARMACEUTICALS INC. COMMON STOCK in Q2 2016, selling an estimated $5.51M.
  • Acuta Capital Partners's ten largest holdings make up 54% of its $208M portfolio in Q2 2016.
  • Acuta Capital Partners opened 35 new positions and closed 7 in Q2 2016.
  • Acuta Capital Partners's portfolio value rose 16% quarter-over-quarter to $208M.

Based on Acuta Capital Partners's 13F filing for Q2 2016, filed 15 Aug 2016.